Assays for detecting hepatitis B virus envelope antigens or antibodies thereto and diagnostic test kits for use in performing the assays

• US 5,620,844 A
• Filed: 05/03/1993
• Issued: 04/15/1997
• Est. Priority Date: 03/07/1984
• Status: Expired due to Fees

• Current Assignee: California Institute of Technology, New York Blood Center Incorporated
• Original Assignee: California Institute of Technology, New York Blood Center Incorporated
• Inventors: Kent, Stephen B. H., Neurath, Alexander R.
• Primary Examiner(s): Caputa, Anthony C.
• Application Number:
  US08/057,200
• Time in Patent Office: 1,443 Days
• Field of Search: 424/89, 424/86, 424/227.1, 424/149.1, 435/5, 435/7.1, 435/7.92, 435/7.93, 435/7.94, 435/7.95, 435/975, 530/324, 530/325, 530/326, 530/327, 530/328, 530/329, 530/330, 530/350, 436/518, 436/524, 436/804
• US Class Current: 435/5
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 47/58 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 16/082 Hepadnaviridae, e.g. hepatitis B virus
• CPC Class Codes: C12N 2730/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: G01N 33/5761 Hepatitis B
• CPC Class Codes: G01N 33/5764 Hepatitis B surface antigen

Abstract

A hepatitis B vaccine containing a peptide with an amino acid chain of at least six consecutive amino acids within the pre-S gene coded region of the envelope of hepatitis B virus. The vaccine being free of an amino acid sequence corresponding to the naturally occurring envelope proteins of hepatitis B virus and a physiologically acceptable diluent. The peptide being free or linked to a carrier. The carrier being a conventional carrier or a novel carrier including a lipid vesicle stabilized by cross-linking and having covalently bonded active sites on the outer surface thereon. Such novel carrier being useful not only to link the novel peptide containing an amino acid chain with amino acids within the pre-S gene coded region of the surface antigen of hepatitis B virus, but can also be used to bind synthetic peptide analogues of other viral proteins, as well as bacterial, allergen and parasitic proteins of man and animals. The peptides of the invention can be utilized in diagnostics for the detection of antigens and antibodies.

Claims

1. A process for the detection of antigens coded for by the pre-S gene in a sample comprising:

(a) coating a solid substrate with antibodies to a peptide, said peptide consisting of an amino acid sequence selected from the group consisting of pre-S (12-47), pre-S (21-47), pre-S (132-137), pre-S (53-73) and pre-S (128-139) of the envelope of hepatitis B virus;

(b) washing the coated substrate;

(c) contacting the washed coated substrate with a protein-containing solution to block non-specific binding sites;

(d) washing the substrate resulting from step (c);

(e) incubating the substrate resulting from step (d) with said sample to bind any pre-S antigen from said sample;

(f) washing the substrate resulting from step (e);

(g) adding radiolabeled or enzyme labeled antibody, said antibody being an antibody to said peptide or hepatitis B surface antigen, to the substrate resulting from step (f);

(h) incubating the substrate resulting from step (g);

(i) washing the substrate resulting from step (h); and

either;

(j1) subjecting the substrate of step (i) to counting in a gamma counter wherein the presence of radioactivity as compared with a normal sera utilized as a control to steps (a) through (i) indicates the presence of antigens coded for by the pre-S gene in said sample;

or

(j2) incubating the substrate of step (i) with a substance that can be converted by the enzyme labeled antibody to a detectable product, and measuring the detectable product wherein the presence of the detectable product as compared with a normal sera control indicates the presence of antigens coded for by the pre-S gene in said sample.

2. The process according to claim 1, wherein said substrate comprises polystyrene beads.

3. The process according to claim 1, wherein said protein-containing solution contains an ingredient selected from the group consisting of bovine serum albumin and gelatin.

4. A process for the detection of antibodies to the pre-S region of hepatitis B virus in a sample comprising:

(a) adsorbing on a solid substrate, a peptide, said peptide consisting of an amino acid sequence selected from the group consisting of pre-S (12-47), pre-S (21-47), pre-S (132-137), pre-S (53-73) and pre-S (128-139) of the envelope of hepatitis B virus;

(b) contacting the substrate resulting from step (a) with a protein containing solution to block non-specific binding sites;

(c) washing the substrate resulting from step (b);

(d) contacting and incubating the substrate resulting from step (c) with a specimen comprising human sera to form a first complex comprising the substrate formed in step (c) specifically bound by antibodies present in said human sera;

(e) washing the first complex of step (d);

(f) adding radiolabeled or enzyme labeled antibodies to human IgG or IgM to the first complex of step (e), to form a second complex and either;

(g1) subjecting the second complex of step (f) to counting in a gamma counter wherein the presence of radioactivity as compared with a normal sera utilized as a control to steps (a) through (g1) indicates the presence of antibodies to the pre-S region of hepatitis B virus in a sample;

or

(g2) incubating the second complex of step (f) with a substance that can be converted by the enzyme labeled antibody to a detectable product, and measuring the detectable product wherein the presence of the detectable product as compared with a normal sera utilized as a control to steps (a) through (g2) indicates the presence of antibodies to the pre-S region of hepatitis B virus in a sample.

5. The process according to claim 4, wherein the substrate comprises polystyrene beads.

6. A process for the detecting antibodies to the pre-S region of hepatitis B virus in a sample comprising:

(a) contacting the sample with a solid substrate coated with a non-labelled peptide, said peptide consisting of an amino acid sequence selected from the group consisting of pre-S (12-47), pre-S (21-47), pre-S (132-137), pre-S (53-73) and pre-S (128-139) of the envelope of hepatitis B virus, incubating the sample and the solid substrate to specifically bind antibodies in the sample to the solid substrate to form a first complex on the solid substrate, and washing said first complex;

(b) contacting the incubated washed first complex obtained from step (a) above with a labelled peptide, said labelled peptide comprising a peptide according to step (a), incubating the washed first complex with said labelled peptide to obtain a second complex and washing the second complex; and

(c) determining the extent of labelled peptide present in the second complex wherein the presence of labelled peptide indicates the presence of antibodies to the pre-S region of hepatitis B virus in a sample.

7. The process according to claim 6, wherein non-specific binding sites on the solid substrate are blocked with a protein solution.

8. A process according to claim 7 wherein the protein of the protein solution comprises albumin.

9. A process for the detection of an antigen coded for by the pre-S gene in a specimen comprising:

(a) contacting said specimen with a composition comprising a labelled peptide and an antibody which binds to said peptide wherein said antibody is produced by introducing said peptide into a animal or human, said peptide consisting of an amino acid sequence selected from the group consisting of pre-S (12-47), pre-S (21-47), pre-S (132-137), pre-S (53-73) and pre-S (128-139) of the envelope of hepatitis B virus, incubating the specimen with said composition to form a first sample complex of said antibody and said labeled peptide;

(b) contacting a control sample free of antigens coded for by the pre-S gene with said composition comprising said labelled peptide and said antibody, incubating the control sample with said composition to form a first control complex;

(c) adding the same amount of Staphylococci bearing protein A to bind each of the complexes formed in step (a) and (b) above, and incubating to form a second sample complex and second control complex respectively, and;

(d) determining the amount of the labelled peptide in each of the second complexes from step (c) above; and

(e) comparing the relative amount of labelled peptides in each of the second complexes from step (c) wherein a decreased amount of labelled peptide in the second sample complex as compared to the second control complex indicates that said specimen contains an antigen coded for by the pre-S gene.

10. A diagnostic test kit for detecting hepatitis B virus, hepatitis B surface antigen or an antigen coded for by the pre-S gene in a test sample comprising in one or more containers:

(a) a given amount of antibody to a peptide, said peptide consisting of an amino acid sequence selected from the group consisting of pre-S (12-47), pre-S (21-47), pre-S (132-137), pre-S (53-73) and pre-S (128-139) of the envelope of hepatitis B virus, the antibody being bound to a solid support; and

(b) a labelled antibody to the peptide or to hepatitis B virus.

11. A diagnostic test kit according to claim 10, which further comprises a set of instructions for performing an immunoassay.

12. A diagnostic test kit for detecting the presence of antibodies to a pre-S gene coded peptide of hepatitis B virus comprising in one or more containers:

(a) a given amount of peptide, said peptide consisting of an amino acid sequence selected from the group consisting of pre-S (12-47), pre-S (21-47), pre-S (132-137), pre-S (53-73) and pre-S (128-139) of the envelope of hepatitis B virus, said peptide bound to a solid support; and

either

(b1) labelled antibodies to human IgG or IgM;

or

(b2) a labelled peptide, said peptide being the peptide of (a).

13. A diagnostic test kit according to claim 12, which further comprises a set of instructions for performing an immunoassay.